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Abstract
Background: Genes encoding cytokine mediators are prime candidates for genetic analysis in
conditions with T-helper (Th) cell disease driven imbalance. Idiopathic Pulmonary Fibrosis (IPF) is
a predominantly Th2 mediated disease associated with a paucity of interferon-gamma (IFN-γ). The
paucity of IFN-γ may favor the development of progressive fibrosis in IPF. Interleukin-12 (IL-12)
plays a key role in inducing IFN-γ production. The aim of the current study was to assess whether
the 1188 (A/C) 3'UTR single nucleotide polymorphism (SNP) in the IL-12 p40 subunit gene which
was recently found to be functional and the 5644 (G/A) 3' UTR SNP of the IFN-γ gene were
associated with susceptibility to IPF.
Methods: We investigated the allelic distribution in these loci in UK white Caucasoid subjects
comprising 73 patients with IPF and 157 healthy controls. The SNPs were determined using the
polymerase chain reaction in association with sequence-specific primers incorporating mismatches
at the 3'-end.
Results: Our results showed that these polymorphisms were distributed similarly in the IPF and
control groups
Conclusion: We conclude that these two potentially important candidate gene single nucleotide
polymorphisms are not associated with susceptibility to IPF.
Introduction
Over the last few years there is accumulating evidence to
support the paradigm that a complex network of
cytokines, produced by activated CD4+ cells, governs the
initiation, maintenance and resolution of an immune
response [1]. CD4+ T cells can be distinguished, based on
their pattern of cytokine production, into T helper (Th)1
and (Th)2. Th1 cells secrete Interleukin (IL)-2 and IFN-γ,
thus promoting cell-mediated immunity whereas Th2
cells produce IL-4, 5,10 and 13 thereby facilitating
humoral immunity [2,3].
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IL-12 plays a key role in promoting Th1 responses. This
cytokine, produced primarily by antigen-presenting cells
is a 75-kDa heterodimer composed of two disulfide-
linked subunits designated p35 and p40, which are
encoded by separate genes on chromosomes 3p12-3q13.2
and 5q31-33 respectively [4]. IL-12 up-regulates IFN-γ
production, and IFN-γ is a powerful co-stimulator of IL-12
production [5]. Thus, a powerful positive feedback loop
can develop between these cytokines that has been shown
to drive type 1 immune responses in a variety of infectious
diseases and many autoimmune processes [5–7]. Defi-
ciency of this feedback might result in a shift towards a
Th2 response.
A number of studies have shown that idiopathic pulmo-
nary fibrosis (IPF) is characterized by a predominance of
gene expression for Th2-type regulatory cytokines. This
pattern is associated with high levels of IL-4 and IL-5 and
a paucity of IFN-γ [8–10]. The paucity of IFN-γ, known for
its anti-fibrotic properties, may contribute to the excessive
fibroblast activation, deposition of collagen and scar for-
mation that occurs in IPF.
Hereditary factors may contribute to the risk of develop-
ing IPF, although no specific genetic abnormality has
been identified yet except in isolated families. However,
the existence of familial pulmonary fibrosis, the presence
of alveolar inflammation in clinically unaffected family
members of patients with familial IPF and the appearance
of IPF-like disease in association with inherited disorders
suggest a genetic predisposition [11,12].
Genes encoding cytokines, which strongly influence the
course of T cell mediated immune responses, are prime
candidates for study in conditions where there is an
imbalance in the T helper cytokine profile. Polymor-
phisms in a range of human cytokine genes have been cor-
related with different levels of protein production,
transplant rejection, fibrosis and autoimmunity [13–16].
Recently, a complete genomic sequence analysis of the IL-
12 gene encoding its p40 subunit identified several
intronic polymorphisms and a Taq I (A/C) single nucle-
otide polymorphism in the 3' untranslated region of the
IL-12  p40 gene at position 1188 [17] which was also
found by another group [18]. This polymorphism was
recently found to be functional [19] and associated with
susceptibility to insulin dependent diabetes mellitus and
multiple sclerosis [20,21]. Wu et al, [22] have described a
G/A polymorphism at position 5644 in the 3' untrans-
lated region of the IFN-γ gene (Accession No, M37265).
Bream et al suggest that this SNP is located in the 3'flank-
ing region [23] but De Capei et al [24] positions the poly-
morphism in the 3'UTR, consistent with Wu et al.
The 3'UTR region plays an important role in the expres-
sion of many eukaryotic genes by governing mRNA stabil-
ity, localizing mRNA, and regulating translation efficiency
and any polymorphism in this region of the gene might
affect gene expression.
Against this background, we examined the distribution of
these two 3'UTR polymorphisms, selected because one of
them has been shown to be functional and the other
located in a region that likely affects mRNA stability in 73
IPF patients and 157 healthy controls.
Methods
Patients
IPF patients were selected to be white UK Caucasians. The
mean age of the IPF patients (n = 73) was 62.5 ± 1.1 years
(56 males and 17 females).
The diagnosis of IPF was made using the ATS/ERS defini-
tion criteria: exclusion of all known causes or associations
with lung fibrosis; bilateral crackles on auscultation; the
presence of typical features on chest high resolution com-
puterized tomography, a restrictive pulmonary deficit
and/or reduced gas transfer measurements, and the
absence of bronchoalveolar lavage features that might
suggest an alternative diagnosis. In 23 of 73 patients, the
diagnosis of fibrosing alveolitis was confirmed by surgical
biopsy.
Informed patient consent was obtained from all subjects
and authorization was given by the Ethics Committee of
the Royal Brompton Hospital.
Control subjects
All control subjects (n = 157) were white UK Caucasian
cadaveric renal allograft donors collected at the Oxford
Transplant Centre (Churchill Hospital, Oxford). The rep-
resentative nature of this control population for UK Cau-
casians has previously been demonstrated in HLA
genotyping studies [25].
Sequence Specific Primers-Polymerase Chain Reaction 
(SSP-PCR)
Polymorphisms were determined using SSP-PCR method-
ology that utilizes sequence specific primers with 3'-end
mismatches and identifies the presence of specific allelic
variants, by PCR amplification.
For the identification of the IL-12 biallelic polymorphism
corresponding to position 1188 (A/C) we used the
sequence-specific reverse primers: 5'TTG TTT CAA TGA
GCA TTT AGC ATC T and 5' GTT TCA ATG AGC ATT TAG
CAT CG in combination with the consensus forward
primer 5'ATC TTG GAG CGA ATG GGC AT at a finalRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/6
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concentration of 3.8 µg/µl with an expected product size
of 780 bp.
The  IFN-γ polymorphism at position 5644 (A/G) was
identified by the sequence-specific forward primers:
5'CCT TCC TAT TTC CTC CTT CG and 5'ACC TTC CTA
TTT CCT CCT TCA in combination with the consensus
reverse primer 5'GTC TAC AAC AGC ACC AGG C at a final
concentration of 7.7 µg/µl with an expected product size
of 298 bp. IL-12 specific primers were used in conjunction
with control primers amplifying a 256-bp fragment of the
human adenomatous polyposis coli gene (primers 210/
211) and the IFN-γ primers in conjunction with control
primer mix amplifying a 796-bp fragment of the DRB
gene (primers 63/64) [26,27]. All PCR reactions were car-
ried out under identical conditions and as previously
described [26,27].
Data Analysis
The genotype frequencies, allele carriage frequency and
allelic frequency were determined by direct counting and
they were compared with those in the control population
initially using a 2 × 3 genotype contingency table and chi2
followed by a 2 × 2 contingency table and chi2 analysis for
the individual positions. A p value less than 0.05 was con-
sidered significant. Statistical power calculations were car-
ried out using the PS Program [28].
Estimate of power for a genetic association study is
dependent on allelic frequency and the proportion of the
phenotypic variant attributed to the allele (relative risk).
On the basis of our patient sample size (n = 73), the ratio
of controls to cases, the frequency of rarer alleles in the
control population IL-12 (0.23) and IFN-γ (0.4), we esti-
mated that for our study to achieve 80% power at 5% sig-
nificance the relative risk attributed to the rarer allele has
to be 2.352 (95% Confidence Interval [CI] 1.79–3.01) for
IL-12 and 2.2 (95% CI 1.6–2.94) for IFN-γ. For a moder-
ate statistical power of 60% an attributable relative risk of
1.97 (95% CI 1.51–2.53) for IL-12 and 1.88 (95% CI,
1.4–2.5) for IFN-γ was required.
Results
Tables 1 and 2 summarize the genotype, and allele fre-
quencies for IL-12 p40 and IFN-γ gene polymorphisms in
patients with IPF and controls.
Both polymorphisms, in all study populations, were in
Hardy-Weinberg equilibrium.
Comparisons between the genotype and allelic frequen-
cies in the IPF and control populations did not reveal
significant frequency differences between the two groups
either for the IL-12 p40 or IFN-γ polymorphisms.
Table 1: Genotype and allele frequencies of the IL-12 p40 gene, position 1188 3'UTR polymorphism in patients with IPF and controls
Genotype IPF [n = 73] (%) Controls [n = 157] (%)
AA 43 (59) 96 (61)
AC 28 (38) 50 (32)
CC 2 (3) 11 (7)
Allele
A 114 (78) 242 (77)
C 32 (22) 72 (23)
Percentages are in parentheses p values: no significance, IPF versus control subjects
Table 2: Genotype and allele frequencies of the IFN-γ position 5644 3'UTR polymorphism in patients with IPF and controls
Genotype IPF [n = 73] (%) Controls [n = 157] (%)
AA 29 (40) 56 (36)
AG 36 (49) 77 (49)
GG 8 (11) 24 (15)
Allele
A 94 (64) 189 (60)
G 52 (36) 125 (40)
Percentages are in parentheses p values: no significance, IPF versus control subjectsRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/6
Page 4 of 5
(page number not for citation purposes)
Discussion
The identification of differential cytokine patterns in
patients with IPF or animal models of pulmonary fibrosis
have provided evidence that the imbalance in the expres-
sion of Th1 and Th2 cytokines may be a central mecha-
nism in the development and progression of pulmonary
fibrosis in IPF. Interleukin-12 and IFN-γ play key roles in
this process. Recently, we examined whether allelic vari-
ants in the gene coding for TNF-α, another key mediator
in the development of IPF, contribute to the development
of IPF [26]. A logical progression from that work was to
evaluate whether SNP's located on the genes coding for IL-
12 and IFN-γ are associated with the development of IPF.
In the current study we investigated the distribution of a
polymorphism in the 3'UTR regions (known to affect
mRNA stability) of the IFN-γ gene at position 5644 in the
3'UTR region (Accession No, M37265) and a functional
polymorphism in the IL-12 p40 subunit gene at position
1188 in the 3' UTR region [17–19] in patients with IPF
and healthy controls. No differences were found between
these populations with regard to their allelic distributions.
However, the size of our patient sample (n = 73),
although small for extensive genetic analysis studies is as
large as other studies for a disease as uncommon as IPF.
Our estimates of statistical power indicated that if the dis-
ease phenotype is attributable to the presence of the rarer
allele in the two loci examined, these alleles would have
to confer a relative risk greater than 2.2 for 80% power at
5% significance to be identified with these patient num-
bers. Thus, if these loci have any influence on disease risk,
it must be relatively small.
The rationale of examining IFN-γ and IL-12 gene poly-
morphisms in IPF is supported by a number of studies.
First, Wallace et al have indicated that while there is evi-
dence for both a type 1 (characterized by IFN-γ) and type
2 response (characterized by IL-4 and IL-5) in the lung
interstitial inflammatory cells from patients with IPF, the
type 2 pattern of cytokines appears to predominate [9].
Similarly, Majumdar et al demonstrated, in a quantitative
study of open lung biopsies, that in IPF the ratio of IL-5 to
IFN-γ was significantly higher than in the patients with
fibrosing alveolitis associated with scleroderma (FASSc)
and control subjects, with IFN-γ under-expression in IPF
contributing equally to this increase [8].
Furthermore, Prior and Haslam have reported that in con-
trast with patients with sarcoidosis, a predominantly Th1
disease, very few patients with IPF and FASSc have ele-
vated plasma levels of IFN-γ. However, as in sarcoidosis,
those with the highest levels responded to corticosteroids
[10]. Moller et al, also, have showed that in contrast to
patients with sarcoidosis, only one of six patients with IPF
had detectable levels of IFN-γ in the bronchoalveolar lav-
age fluid (BAL). In addition, IL-12 p40 protein was
detected in BAL from four of six patients with IPF. How-
ever, although not significantly different, the median level
was less than half that observed in sarcoidosis. In contrast,
significantly higher levels of IL-10 were found in BAL fluid
from patients with IPF than from patients with sarcoidosis
and normal controls, indicating that the cytokine profile
between the two diseases is quite different [29].
The paucity of IFN-γ, and the predominance of Th2 type
cytokines (IL-4 is an important mediator of fibroblastic
activation) may favour the development of progressive
fibrosis in IPF. This is supported by the knowledge that
IFN-γ inhibits fibroblast collagen synthesis in vitro
[30,31] and attenuates bleomycin-induced lung fibrosis
in the mouse model of lung fibrosis [32]. Furthermore,
levels of IFN-γ are inversely related to the levels of type III
procollagen in the BAL of IPF patients [33].
IL-12 has been shown to play a central role in the devel-
opment of type 1 immune responses. Thus, deficient IL-
12 activity may result in a shift towards a Th2 response.
The IL-12 p40 subunit gene at position 1188 3'UTR region
has already been examined in a number of autoimmune
diseases. Hall et al showed that this polymorphism was
not associated with rheumatoid arthritis, Felty's syndrome
or large granular lymphocyte syndrome with arthritis or
multiple sclerosis [18]. However, in other studies the pol-
ymorphism was found to be associated with susceptibility
to multiple sclerosis and type 1 diabetes mellitus. [20,21].
Polymorphisms in the human cytokine genes have been
associated with different levels of protein production.
Recent studies have shown that the 1188 3'UTR IL-12 p40
polymorphic site is biologically relevant. Seegers et al have
demonstrated that the presence of the rarer allele was cor-
related with increased IL-12 p70 secretion by stimulated
monocytes [19].
Surprisingly, a recent study has found that the proximal
promoter and exonic regions of the IFN-γ gene are invari-
ant in a Caucasian cohort [23]. In the same study, of the
three intronic and one 3'UTR single nucleotide variations
identified, only the alleles in the 3'UTR locus altered tran-
scription element DNA-binding ability. This suggests that
this region of the gene could be of vital importance in the
regulation of IFN-γ gene expression.
Although in the current study we did not observe an asso-
ciation between the polymorphic loci examined and IPF,
we cannot exclude that other polymorphic variations
within these genes [17,23] or their receptors [34] may
denote susceptibility to IPF. In this regard, Tanaka et al
have reported that a polymorphism within the IFN-γ
receptor gene may result in a shift to Th2 response andRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/6
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this shift may increase susceptibility to systemic lupus ery-
thematosus [34]. Thus, further studies are needed to eval-
uate whether other polymorphisms in genes regulating IL-
12 and IFN-γ production are involved in IPF susceptibility
and the present study, although negative, will hopefully
direct subsequent work in this direction.
Conclusion
In conclusion, in the current study we evaluated the distri-
bution of single nucleotide polymorphisms in the 3'UTR
region of two important candidate gene – IL-12 and IFN-
γ-but found no direct association with susceptibility to
IPF. However, further studies are needed to establish
whether the under representation of these mediators in
IPF is linked to other genetic variations in genes coding for
proteins associated with their regulation.
Abbreviations
IL-12 = Interleukin 12, IFN-γ = Interferon – gamma IPF =
Idiopathic Pulmonary Fibrosis 3'UTR = 3' Untranslated
Region
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